Comparison of Plasminogen Activator Inhibitor-1, Tissue Type Plasminogen Activator Antigen, Fibrinogen, and D-Dimer Levels in Various Age Decades in Patients With Type 2 Diabetes Mellitus and Stable Coronary Artery Disease (from the BARI 2D Trial)

American Journal of Cardiology

Volumn 105, Issue 1, 2010, Pages 17-24

  McBane II, Robert D ^a   Hardison, Regina M ^b   Sobel, Burton E ^c  

^a MAYO CLINIC   (United States)

^b UNIVERSITY OF PITTSBURGH   (United States)

^c UNIVERSITY OF VERMONT   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

D DIMER; FIBRINOGEN; PLASMINOGEN ACTIVATOR INHIBITOR 1; TISSUE PLASMINOGEN ACTIVATOR;

ADULT; AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; CORONARY ARTERY DISEASE; DIABETIC PATIENT; ETHNICITY; FEMALE; FIBRINOLYSIS; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; SURVIVAL;

AGE FACTORS; AGED; AUTOANTIGENS; CORONARY ARTERY DISEASE; DIABETES MELLITUS, TYPE 2; DISEASE PROGRESSION; FEMALE; FIBRIN FIBRINOGEN DEGRADATION PRODUCTS; FIBRINOGEN; FIBRINOLYSIS; FOLLOW-UP STUDIES; HUMANS; MALE; MIDDLE AGED; PLASMINOGEN ACTIVATOR INHIBITOR 1; RETROSPECTIVE STUDIES; RISK FACTORS; SEVERITY OF ILLNESS INDEX; TIME FACTORS; TISSUE PLASMINOGEN ACTIVATOR;

EID: 72049086923     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2009.08.643     Document Type: Article

References (25)

1. Sobel B.E., Frye R., Detre K.M., and Bypass Angioplasty Revascularization Investigation 2 Diabetes trial. Burgeoning dilemmas in the management of diabetes and cardiovascular disease: rationale for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Circulation 107 (2003) 636-642
2. Brooks M.M., Frye R.L., Genuth S., Detre K.M., Nesto R., Sobel B.E., Kelsey S.F., Orchard T.J., and Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) Trial Investigators. Hypotheses, design, and methods for the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial. Am J Cardiol 97 (2006) 9G-19G
3. Sobel E., and BARI 2D Trial investigators. Ancillary studies in the Bypass Angioplasty Revascularization Investigation 2 Diabetes (BARI 2D) trial: synergies and opportunities. Am J Cardiol 97 (2006) 53G-58G
4. Kruszynska Y., Yu J.G., Sobel B.E., and Olefsky J.M. Effects of troglitazone on blood concentrations of plasminogen activator inhibitor 1 in patients with type 2 diabetes mellitus and in lean and obese normal subjects. Diabetes 49 (2000) 633-639
5. Yamamoto K., Takeshita K., Kojima T., Takamatsu J., and Saito H. Aging and plasmiongen activator inhibitor-1 (PAI-1) regulation: implication in the pathogenesis of thrombotic disorders in the elderly. Cardiovasc Res 66 (2005) 276-285
6. Hamsten A., de Faire U., Walldius G., Dahlén G., Szamosi A., Landou C., Blombäck M., and Wiman B. Plasminogen activator inhibitor in plasma: risk factor for recurrent myocardial infarction. Lancet 2 (1987) 3-9
7. Mannucci P.M., Bernardinelli L., Foco L., Galli M., Ribichini F., Tubaro M., and Peyvandi F. Tissue plasminogen activator antigen is strongly associated with myocardial infarction in young women. J Thromb Haemost 3 (2005) 280-286
8. Thögersen A.M., Jansson J.H., Boman K., Nilsson T.K., Weinehall L., Huhtasaari F., and Hallmans G. High plasminogen activator inhibitor and tissue plasminogen activator levels in plasma precede a first acute myocardial infarction in both men and women: evidence for the fibrinolytic system as an independent primary risk factor. Circulation 98 (1998) 2241-2247
9. Festa A., Williams K., Tracy R.P., Wagenknecht L.E., and Haffner S.M. Progression of plasminogen activator inhibitor-1 and fibrinogen levels in relation to incident type 2 diabetes. Circulation 113 (2006) 1753-1759
10. Gurlek A., Bayraktar M., and Kirazli S. Increased plasminogen activator inhibitor-1 activity in offspring of type 2 diabetic patients: lack of association with plasma insulin levels. Diabetes Care 23 (2000) 88-92
11. Tofler G.H., Massaro J., Levy D., Mittleman M., Sutherland P., Lipinska I., Muller J.E., and D'Agostino R.B. Relation of the prothrombotic state to increasing age (from the Framingham Offspring Study). Am J Cardiol 96 (2005) 1280-1283
12. Asselbergs F.W., Williams S.M., Hebert P.R., Coffey C.S., Hillege H.L., Snieder H., Navis G., Vaughan D.E., van Gilst W.H., and Moore J.H. The effects of polymorphisms in genes from the renin-angiotensin, bradykinin, and fibrinolytic systems on plasma t-PA and PAI-1 levels are dependent on environmental context. Hum Genet 122 (2007) 275-281
13. Mansfield M.W., Stickland M.H., and Grant P.J. Environmental and genetic factors in relation to elevated circulating levels of plasminogen activator inhibitor-1 in Caucasian patients with non-insulin-dependent diabetes mellitus. Thromb Haemost 74 (1995) 842-847
14. Folsom A.R., Wu K.K., Rosamond W.D., Sharrett A.R., and Chambless L.E. Prospective study of hemostatic factors and incidence of coronary heart disease: the Atherosclerosis Risk in Communities (ARIC) study. Circulation 96 (1997) 1102-1108
15. Bogaty P., Poirier P., Simard S., Boyer L., Solymoss S., and Dagenais G.R. Biological profiles in subjects with recurrent acute coronary events compared with subjects with long-standing stable angina. Circulation 103 (2001) 3062-3068
16. Gallistl S., Sudi K.M., Borkenstein M., Troebinger M., Weinhandl G., and Muntean W. Determinants of haemostatic risk factors for coronary heart disease in obese children and adolescents. Internation J Obes 24 (2000) 1459-1464
17. Van Guilder G.P., Hoetzer G.L., Smith D.T., Irmiger H.M., Greiner J.J., Stauffer B.L., and DeSouza C.A. Endothelial t-PA release is impaired in overweight and obese adults but can be improved with regular aerobic exercise. Am J Physiol-End Metab 289 (2005) E807-E813
18. Rosito G.A., D'Agostino R.B., Massaro J., Lipinska I., Mittleman M.A., Sutherland P., Wilson P.W., Levy D., Muller J.E., and Tofler G.H. Association between obesity and a prothrombotic state: the Framingham Offspring Study. Thromb Haemost 91 (2004) 683-689
19. Asselbergs F.W., Williams S.M., Hebert P.R., Coffey C.S., Hillege H.L., Navis G., Vaughan D.E., van Gilst W.H., and Moore J.H. Gender specific correlations of PAI-1 and t-PA levels with cardiovascular disease-related traits. J Thromb Haemost 5 (2007) 313-320
20. Asselbergs F.W., Williams S.M., Hebert P.R., Coffey C.S., Hillege H.L., Navis G., Vaughan D.E., van Gilst W.H., and Moore J.H. The gender-specific role of polymorphisms from the fibrinolytic, renin-angiotensin, and bradykinin systems in determining plasma t-PA and PAI-1 levels. Thromb Haemost 96 (2006) 471-477
21. Kalaria V.G., Zareba W., Moss A.J., Pancio G., Marder V.J., Morrissey J.H., Weiss H.J., Sparks C.E., Greenberg H., Dwyer E., Goldstein R., and Watelet L.F. Gender-related differences in thrombogenic factors predicting recurrent cardiac events in patients after acute myocardial infarction. Am J Cardiol 85 (2000) 1401-1408
22. Perry A., Wang X., Goldberg R., Ross R., and Jackson L. The relationship between cardiometabolic and hemostatic variables: influence of race. Metabolism 57 (2008) 200-206
23. Ajjan R., Carter A.M., Somani R., Kain K., and Grant P.J. Ethnic differences in cardiovascular risk factors in healthy Caucasian and south Asian individuals with the metabolic syndrome. J Thromb Haemost 5 (2007) 754-760
24. Greyling A., Pieters M., Hoekstra T., Oosthuizen W., and Schutte A.E. Differences in the association of PAI-1 activity with the metabolic syndrome between African and Caucasian women. Nutr Metab Cardiovasc Dis 17 (2007) 499-507
25. Wong T.Y., Islam F.M., Klein R., Klein B.E., Cotch M.F., Castro C., Sharrett A.R., and Shahar E. Retinal vascular caliber, cardiovascular risk factors, and inflammation: the multi-ethnic study of atherosclerosis (MESA). Invest Ophthalmol Vis Sci 47 (2006) 2341-2350